Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The polycythemia vera stem cell

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144–1148.

    CAS  Article  Google Scholar 

  2. 2

    Nussenzveig RH, Jelinek J, Gaikwad A, Liu E, Verstovsek S, Prchal JF et al. Polycythemia vera is not initiated by JAK2V617F mutation. Exp Hematol 2007; 35: 32–38.

    CAS  Article  Google Scholar 

  3. 3

    Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell 2010; 17: 584–596.

    CAS  Article  Google Scholar 

  4. 4

    Theocharides A, Boissinot M, Girodon F, Garand R, Teo SS, Lippert E et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007; 110: 375–379.

    CAS  Article  Google Scholar 

  5. 5

    Stein BL, Williams DM, Wang NY, Rogers O, Isaacs MA, Pemmaraju N et al. Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders. Haematologica 2010; 95: 1090–1097.

    Article  Google Scholar 

  6. 6

    Moliterno AR, Williams DM, Rogers O, Isaacs MA, Spivak JL . Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens. Exp Hematol 2008; 36: 1480–1486.

    CAS  Article  Google Scholar 

  7. 7

    Stein BL, Williams DM, Rogers O, Isaacs MA, Spivak JL, Moliterno AR . Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients. Exp Hematol 2011; 39: 95–101.

    CAS  Article  Google Scholar 

  8. 8

    Gerber JM, Ngwang B, Zhang H, Williams DM, Rogers O, Jones RJ et al. The leukemic stem cell in polycythemia vera and primary myelofibrosis is distinct from the initiating JAK2 V617F-positive hematopoietic stem cell. Blood 2011; 118: 613a.

    Article  Google Scholar 

  9. 9

    Spivak JL, Williams DM, Rogers O, Considine M, Ochs M, Moliterno AR et al. A molecular basis for risk stratification in polycythemia vera. Blood 2012; 120: 429a.

    Article  Google Scholar 

Download references

Acknowledgements

The symposium and publication of this supplement were sponsored by the Division of Hematology/Oncology at the Warren Alpert Medical School of Brown University and NIH Center of Biomedical Research Excellence (COBRE) for Stem Cells Biology at Rhode Island Hospital. JLS received grant support from National Cancer Institute Program Project PO1-CA108671.

Author information

Affiliations

Authors

Corresponding author

Correspondence to J L Spivak.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Spivak, J. The polycythemia vera stem cell. Leukemia Suppl 3, S23–S24 (2014). https://doi.org/10.1038/leusup.2014.13

Download citation

Keywords

  • PV initiating stem cell
  • JAK2 V617F mutation
  • ALDH activity in stem cells

Search

Quick links